



www.asianpubs.org

ARTICLE

Zirconia Nanoparticles Catalyzed Multi-Component Synthesis of Functionalized Chromene-pyrazolone Derivatives

Santosh A. Jadhav¹, Anil V. Raut², Mazahar Farooqui³,
Devanand B. Shinde⁴, Aniket P. Sarkate⁴ and
Rajendra K. Pardeshi^{5,✉}

ABSTRACT

The compounds **4a-m** (functionalized chromene phenyl pyrazolone derivatives) were synthesized using ultrafine zirconia nanoparticles (ZrO₂ NPs) by multi-component approach in water-ethanol as green solvent. Zirconia nanoparticles gave good catalytic activity for first four cycles of synthesized product. The structural and morphological characterizations of the as-prepared ZrO₂ nanoparticles were performed by using X-ray diffraction, Fourier transform infrared spectroscopy, energy dispersive X-ray microanalysis (EDS) spectroscopy and Ultraviolet visible (UV-visible) absorption spectroscopy. The morphological property revealed the formation of nanoscale particles. In this investigation we gave emphasis on the eco-friendly synthesis of chromene-phenyl pyrazolones derivatives using ZrO₂ nanoparticles and water-ethanol. The expected results reveals the applicability of tuneable catalytic activity, reaction time and the reusability of ZrO₂ nanoparticles even after several cycles.

KEYWORDS

ZrO₂ nanoparticles, Green solvent, Multi-component, Chromene phenyl pyrazolones.

INTRODUCTION

The chromene scaffold is a central part of many biologically active compounds with potential medicinal use as antitumor [1], antimicrobial [2], antitrypanosomal agents [3], antimicrobial, antibiofilm activities [4], potential NF-κB inhibitors [5], in molluscicidal activity [6], antioxidant [7], antifungal [8], antiprotozoal activity [9]. Now days, multi-component reactions (MCRs) are accepted worldwide as an important tool for the synthesis of various products and intermediates in medicinal and combinatorial chemistry [10,11].

These reactions avoid time consuming and multistep process [12,13], have been proven to be graceful and rapid way to shows advantage of atom economy and high selectivity [14]. The condensation reaction of active methylene group with aldehyde function of 3-formyl chromene was studied by different workers [15] but these studies has some limitations such as use of hazardous acid or base catalyst, longer heating

Asian Journal of Organic & Medicinal Chemistry

Volume: 1 Year: 2016
Issue: 3 Month: July-September
pp: 91-96
DOI: <http://dx.doi.org/10.14233/ajomc.2016.AJOMC-P28>

Received: 9 September 2016
Accepted: 22 September 2016
Published: 13 October 2016

Author affiliations:

¹Department of Chemistry, Vivekanand College, Aurangabad-431 001, India

²Department of Physics, Vivekanand College, Aurangabad-431 001, India

³Department of Chemistry, Dr. Rafiq Zakaria College for Women Aurangabad-431 001, India

⁴Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad-431 004, India

⁵Department of Chemistry, Sant Ramdas College, Ghansawangi, Jalna-431 209, India

✉To whom correspondence to be addressed:

Fax: +91 2483 231313

E-mail: rajendrakpardeshi@gmail.com; santoshjdv11@gmail.com


Available online at: <http://ajomc.asianpubs.org>

period, low productivity and synthesis required multi-step process [16-18]. To the best of our literature survey, there is no efficient general multi-component protocol for the synthesis of chromene-phenyl pyrazolones derivatives using ZrO₂ nanoparticle (NPs) in green solvent with very short reaction time. The use of ZrO₂ NPs could be more effective due to their reactivity and large surface area. Being a dielectric material, ZrO₂ has a stable tetragonal phase structure in the temperature range of 25-1000 °C. The conductivity of this pure ZrO₂ material is only 10⁻⁷ s/cm at 1000 °C, which is close to the conductivity of insulating material [19]. The present work is an effort in which ZrO₂ NPs in water-ethanol found that best catalyst solvent combination for the synthesis of 3-methyl-4-[(4-oxo-4*H*-chromen-3-yl)-methylene]-1-phenyl-1*H*-pyrazol-5(4*H*)-ones (**Scheme-I**). To explore the catalytic activity of ZrO₂ NPs in elementary organic transformations are available in literature [20,21]. This is the first time attempt for the synthesis of reported chromene pyrazolone derivatives by multi-component single route. Thus we wish to report, a simple and efficient protocol for the synthesis of chromene pyrazolone derivatives by using ZrO₂ NPs as a heterogeneous catalyst in water-ethanol as solvent (**Scheme-I**).

EXPERIMENTAL

The chemicals with 99.9 % purity playing important role in the present synthesis are ethyl acetoacetate, phenyl hydrazine, chromene and catalyst ZrO₂ NPs were purchased from Sigma-Aldrich. An appropriate molar proportion of starting materials was taken and the protocols of standard techniques were followed for the synthesis of multi-component synthesis of functionalized chromene-pyrazolone derivatives using zirconia nanoparticles. Melting points of synthesized product were recorded on OptiMELT digital melting point apparatus and were uncorrected. The elemental analysis was performed on a Perkin Elmer 2400 series II elemental CHN analyzer. All the products were well characterized and comparison of their reported spectral data [16-18]. Spectral data for the entire synthesized product (**4a-4m**) as depicted in table are shown in supplementary data as a supporting data.

General procedure for the synthesis of compounds (4a-m): A mixture of 4-oxo-4*H*-benzopyran-3-carbaldehydes (**1**) (1 mmol), phenyl hydrazine (**2**) (1 mmol), ethyl acetoacetate (**3**) (1 mmol) and ZrO₂ NPs (10 mol %) in 4 mL ethanol water (4:1) was stirred at 60-70 °C for 5-7 min until the reaction mixture solidified. The progress of the reaction was monitored by TLC. After completion of reaction, the solvent was removed under reduced pressure; crude product was stirred with 4-6 mL methanol at 60-70 °C for 5 min followed by the simple filtration to remove catalyst out by simple filtration. Then methanol was removed under reduced pressure and the solid compound was



Scheme-I: Synthesis of 3-methyl-4-[(4-oxo-4*H*-chromen-3-yl)-methylene]-1-phenyl-1*H*-pyrazol-5(4*H*)-ones

purified by recrystallization from absolute ethanol to give product with an excellent yield (**4a**) (97 %).

Procedure of reusability of catalyst: The recovered catalyst from the reaction mixture during the synthesis of chromene pyrazolones derivative was then washed with hot methanol (14 mL) followed by hot ethanol (6 mL) and finally dried well and reused for subsequent runs. The catalytic activity of ZrO₂ NPs remains unchanged even after 8th cycles.

X-ray diffraction: The X-ray diffraction (XRD) patterns was characterized by Philips X'Pert Pro monochromatized diffractometer Cu-K_α radiation ($\lambda = 1.54056 \text{ \AA}$). By X-ray diffraction pattern (Fig. 1), we observed high intensity peak (103) at assigned at $2\theta = 30.5$. (112) and (101) reflections are present at $2\theta = 51.02$ and 59.31 respectively. All the reflections are indexed to the characteristic planes of a major tetragonal phase in ZrO₂ crystal system (t-ZrO₂, space group P21/a, JCPDS card No. 37-1484 and 88-1007) no extra peak was observed corresponding to monoclinic plane. A clear broad peak in powder X-ray diffraction confirmed the formation of nano-sized particles of ZrO₂. The crystallite sizes was estimated from the Debye-Scherrer equation $D = 0.9\lambda/\beta\cos \theta$; where λ is the wavelength of Cu-K_α radiation (1.54056 \AA) and β is the full width of the (h k l) peak at the diffracting angle 2θ . The mean crystallite size was estimated between 20 and 30 nm.




Fig. 1. Powder XRD of ZrO₂ NPs after 8th cycle

UV-visible spectroscopy: In Fig. 2 the UV-visible spectra of pure ZrO₂ NPs and ZrO₂ NPs after 8th cycle were recorded on Scinco UV-visible scanning spectrometer (ModelS-4100) with the wavelength $\lambda =$ about 260 nm (Fig. 2). UV near-band edge (NBE) emission of ZrO₂ were observed at range between 458-465 nm which was equivalent to band gap of 4.76 eV. The electronic band structure of ZrO₂ is strongly influenced by the hybridization of Zr-4*d* orbital and O-2*p* orbital [22]. The interaction of chromene-pyrazolone derivatives with




Fig. 2. UV-Visible spectra of pure ZrO₂ NPs and after 8th cycle

ZrO₂ NPs has noticeable effect in its band structure as revealed by UV-visible spectroscopy.

FT-IR: Fourier transform infrared spectra were recorded on a Perkin-Elmer FT Spectrophotometer in KBr disc (Fig. 3). The distinctive band around 3375.1 cm⁻¹ can be seen which indicated the transmittance due to O-H absorptions. 944.1 cm⁻¹ and a broad band near 1645.4 cm⁻¹ which are associated with the O-H modes of chemisorbed water and/or terminated hydroxides at the surface. The intense absorbance band in FT-IR spectrum were observed in range between 496-490 cm⁻¹ and 450-445 cm⁻¹ which were attributed to the Zr-O stretching vibrations.




Fig. 3. FT-IR spectra of pure ZrO₂ NPs

¹H NMR: The nuclear magnetic resonance spectroscopy of crystalline phases is a powerful alternative technique for materials characterization that probes the atomic structure, complementing diffraction analysis and microscopy methods. The structures of the crystalline phases present in monoclinic and tetragonal ZrO₂ compounds were deduced from their ¹H NMR spectra recorded on Varian 300 MHz spectrophotometer in CDCl₃.

Spectral characterization data of compound 4a-m:

3-Methyl-4-[(5,8-dichloro-4-oxo-4H-chromen-3-yl)methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4a): Light red crystals. Yield: 97 %. m.p.: 291-293 °C. IR (KBr, ν_{max}, cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ-pyrone), 697

(C-Cl); ¹H NMR (300 Mz, CDCl₃): δ = 2.3 (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 7.1 (d, 1H; aromatic O-substituted -Cl), 7.5 (d, 1H; aromatic O-substituted -Cl), ES-MS *m/z* (%): 241.95 M⁺. Anal. calcd. (%) for C₂₀H₁₂N₂O₃Cl₂; C, 60.70; H, 3.03; N, 7.02. Found: C, 60.63; H, 3.13; N, 6.98.

3-Methyl-4-[(6-methyl-4-oxo-4H-chromen-3-yl)methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4b): Orange red crystals. Yield: 84 %; m.p.: 239-241 °C. IR (KBr, ν_{max}, cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ-pyrone); ¹H NMR (300 Mz, CDCl₃): δ = 2.3 (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH), 7.18-7.98 (m, 5H; aromatic), 7.6 (d, 1H; aromatic), 7.65 (d, 1H; aromatic), 7.4 (s, 1H; aromatic), 2.3 (s, 3H; H₃C-Ar), ES-MS *m/z* (%): 344.11 M⁺. Anal. calcd. (%) for C₂₁H₁₆N₂O₃; C, 73.24; H, 4.68; N, 8.13. Found: C, 73.17; H, 4.73; N, 8.03.

4-[(6-Bromo-4-oxo-4H-chromen-3-yl)methylene]-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (4c): Red crystals; Yield: 90 %; m.p.: 234-235 °C; IR (KBr, ν_{max}, cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ-pyrone), 759 (C-Cl); ¹H NMR (300 Mz, CDCl₃): δ = 2.3 (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH), 7.18-7.98 (m, 5H; aromatic), 7.1 (d, 1H; aromatic), 7.7 (d, 1H; aromatic O-substituted -Br), 7.9 (s, 1H; aromatic O-substituted -Br), MS (EI): *m/z* (%): 408.01 M⁺. Anal. calcd. (%) for C₂₀H₁₃N₂O₃Br; C, 58.70; H, 3.20; N, 6.85. Found: C, 58.62; H, 3.27; N, 6.77

4-[(6-Chloro-7-methyl-4-oxo-4H-chromen-3-yl)methylene]-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (4d): Red crystals; Yield: 95 %; m.p.: 252-254 °C; IR (KBr, ν_{max}, cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ-pyrone), 687 (O-substituted methyl and -Cl group). 2885 (aliphatic C-H str.); ¹H NMR (300 Mz, CDCl₃): δ = 2.3 (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH), 7.18-7.98 (m, 5H; aromatic), 7.10 (s, 1H; aromatic), 7.52 (s, 1H; aromatic O-substituted -Cl), 2.3 (s, 3H; C₃H-Ar), MS (EI): *m/z* (%): 378.07 M⁺. Anal. calcd. (%) for C₂₁H₁₅N₂O₃Cl; C, 66.58; H, 3.99; N, 7.40. Found: C, 66.51; H, 4.03; N, 7.31.

4-[(6,7-Dichloro-4-oxo-4H-chromen-3-yl)methylene]-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (4e): Orange red crystals; Yield: 94 %; m.p.: 267-269 °C; IR (KBr, ν_{max}, cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ-pyrone), 697 (o-substituted -Cl group); ¹H NMR (300 Mz, CDCl₃): δ = 2.3 (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 7.3 (s, 1H; aromatic O-substituted -Cl), 7.5 (s, 1H; aromatic O-substituted -Cl), MS (EI): *m/z* (%): 398.02M⁺. Anal. calcd. (%) for C₂₀H₂₂N₂O₃Cl₂; C, 60.17; H, 3.03; N, 7.02. Found: C, 60.01; H, 3.11; N, 6.98.

3-Methyl-4-[(6,7-dimethyl-4-oxo-4H-chromen-3-yl)methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4f): Orange red crystals; Yield: 81 %; m.p.: 249-251 °C; IR (KBr, ν_{max}, cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ-pyrone), 697

(*o*-substituted -Cl group); $^1\text{H NMR}$ (300 Mz, CDCl_3): $\delta = 2.3$ (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 7.0 (s, 1H; aromatic), 7.3 (s, 1H; aromatic), 2.3 (s, 3H; H₃C-Ar), 2.3 (s, 3H; HC₃-Ar), MS (EI): m/z (%): 358.13M⁺. Anal. calcd. (%) for C₂₂H₁₈N₂O₃; C, 73.73; H, 5.06; N, 7.82. Found: C, 73.68; H, 5.13; N, 7.76.

3-Methyl-4-[(8-chloro-4-oxo-4H-chromen-3-yl)-methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4g): Orange red crystals; Yield: 89 %; Orange red crystals; m.p.: 219-221 °C; IR (KBr, ν_{max} , cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ -pyrone), 697 (*o*-substituted -Cl group); $^1\text{H NMR}$ (300 Mz, CDCl_3): $\delta = 2.3$ (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 7.6 (d, 1H; aromatic *O*-substituted -Cl), 7.2 (d, 1H; aromatic), 7.9 (m, 1H; aromatic), MS (EI): m/z (%): 364.06 M⁺. Anal. calcd. (%) for C₂₀H₁₃N₂O₃Cl; C, 65.85; H, 3.59; N, 7.68. Found: C, 65.79; H, 3.66; N, 7.62.

3-Methyl-4-[(6-chloro-4-oxo-4H-chromen-3-yl)-methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4h): Orange red crystals; Yield: 89 %; m.p.: 235-237 °C; IR (KBr, ν_{max} , cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ -pyrone), 697 (*o*-substituted -Cl group); $^1\text{H NMR}$ (300 Mz, CDCl_3): $\delta = 2.3$ (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 8.0 (s, 1H; aromatic *O*-substituted -Cl), 7.8 (d, 1H; aromatic *O*-substituted -Cl), 7.6 (d, 1H; aromatic), MS (EI): m/z (%): 364.06M⁺. Anal. calcd. (%) for C₂₀H₁₃N₂O₃Cl; C, 65.85; H, 3.59; N, 7.68. Found: C, 65.79; H, 3.65; N, 7.61.

3-Methyl-4-[(6,8-dichloro-4-oxo-4H-chromen-3-yl)methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4i): Orange red crystals; Yield: 92 %; m.p.: 292-293 °C; IR (KBr, ν_{max} , cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ -pyrone), 697 (*o*-substituted -Cl group); $^1\text{H NMR}$ (300 Mz, CDCl_3): $\delta = 2.3$ (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 7.8 (s, 1H; aromatic *O*-substituted -Cl), 7.9 (s, 1H; aromatic *O*-substituted -Cl), MS (EI): m/z (%): 398.02M⁺. Anal. calcd. (%) for C₂₀H₁₂N₂O₃Cl₂; C, 60.17; H, 3.03; N, 7.02. Found: C, 60.06; H, 3.12; N, 6.98.

3-Methyl-4-[(7-methyl-4-oxo-4H-chromen-3-yl)-methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4j): Orange red crystals; Yield: 84 %; m.p.: 198-201 °C; IR (KBr, ν_{max} , cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ -pyrone), 697 (*o*-substituted -Cl group); $^1\text{H NMR}$ (300 Mz, CDCl_3): $\delta = 2.3$ (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 7.1 (s, 1H; aromatic), 6.9 (d, 1H; aromatic), 7.6 (d, 1H; aromatic), 2.3 (s, 3H; CH₃-Ar), MS (EI): m/z (%): 344.11M⁺. Anal. calcd. (%) for C₂₁H₁₆N₂O₃; C, 73.24; H, 4.68; N, 8.13. Found: C, 73.17; H, 4.73; N, 8.07.

3-Methyl-4-[(5,7-dimethyl-4-oxo-4H-chromen-3-yl)-methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4k): Orange red crystals; Yield: 80 %; m.p.: 214-215 °C; IR (KBr, ν_{max} ,


cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ -pyrone), 697 (*o*-substituted -Cl group); $^1\text{H NMR}$ (300 Mz, CDCl_3): $\delta = 2.3$ (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 7.0 (s, 1H; aromatic), 6.8 (s, 1H; aromatic), 2.3 (s, 3H; CH₃-Ar), 2.4 (s, 3H; CH₃-Ar), MS (EI): m/z (%): 358.13 M⁺. Anal. calcd. (%) for C₂₂H₁₈N₂O₃; C, 73.73; H, 5.06; N, 7.82. Found: C, 73.67; H, 5.13; N, 7.75.

3-Methyl-4-[(6,8-dimethyl-4-oxo-4H-chromen-3-yl)-methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4l): Orange red crystals; Yield: 82 %; m.p.: 280-283 °C; IR (KBr, ν_{max} , cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ -pyrone), 697 (*o*-substituted -Cl group); $^1\text{H NMR}$ (300 Mz, CDCl_3): $\delta = 2.3$ (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 7.2 (s, 1H; aromatic), 7.1 (s, 1H; aromatic), 2.1 (s, 3H; CH₃-Ar), 2.3 (s, 3H; CH₃-Ar), MS (EI): m/z (%): 358.13M⁺. Anal. calcd. (%) for C₂₂H₁₈N₂O₃; C, 73.73; H, 5.06; N, 7.82. Found: C, 73.65; H, 5.14; N, 7.76.

3-Methyl-4-[(4-oxo-4H-chromen-3-yl) methylene]-1-phenyl-1H-pyrazol-5(4H)-one (4m): Orange red crystals; Yield: 86 %; m.p.: 229-231 °C; IR (KBr, ν_{max} , cm⁻¹): 3065 (=C-H, Ar-H), 1795 (C=O, pyrazolinyl), 1689 (C=N, pyrazolinyl), 1665 (C=O, chromone), 1463 (γ -pyrone), 697 (*o*-substituted -Cl group); $^1\text{H NMR}$ (300 Mz, CDCl_3): $\delta = 2.3$ (s, 3H, -CH₃; pyrazolinyl), 6.7 (s, 1H, -CH-O; chromone moiety), 7.4 (s, 1H, -CH=CH).7.18-7.98 (m, 5H; aromatic), 7.45-8.10 (m, 4H; aromatic), MS (EI): m/z (%): 330.1M⁺. Anal. calcd. (%) for C₂₀H₁₄N₂O₃; C, 72.72; H, 4.27; N, 8.48. Found: C, 72.63; H, 4.33; N, 8.37.

RESULTS AND DISCUSSION

Keeping focus on multicomponent green approach, we choose ZrO₂ NPs for the optimization reaction condition with various solvent (Table-1). In ethanol, good yield of product was obtained (Table-1, entry 9), on this result, if we used water in ethanol as the ethanol-water (4:1) an excellent yield was obtained in 10 mol % ZrO₂ NPs within 5 min (Table-1, entry 12). While, increasing or decreasing amount of ethanol in a set of water, the yield of product was reduced (Table-1, entries 10, 11, 14, 15) in different proportion of catalyst. This is due to the surface area of the NPs being more active in polar-protic solvents and presence of oxygen vacancies, which are responsible for stability and higher surface activity [23]. Further we focus on significant effect of time and amount of catalyst on yield of reaction, the yield of product was fall down by decreasing time of reaction, while no significant change was observed by increasing the time of reaction (Table-1, entry 12). Further we changed amount of catalyst, less than 10 mol % or greater than 10 mole % no significant yield was obtained (Table-1, entries 11, 13). The yield of product was decreases while decreasing amount of ethanol in ethanol-water solvent (Table-1, entries 13-15). Thus, all examples were tested reasonably well to the excellent yields in ethanol water (4:1) with 10 mol % of catalyst (Table-2) (**Scheme-II**). The catalyst



Scheme-II: Yields in ethanol water (4:1) with 10 mol % of catalyst

TABLE-1
SCREENING OF CATALYST WITH SOLVENTS, REACTION TIME AND YIELD FOR THE SYNTHESIS OF COMPOUND 4a

Entry	Catalyst (10 mol %)	Solvent	Time (min)	Yield (%) ^a
1	Without	Solvent free	120	00
2	ZrO ₂ NPs	Solvent free	60	30
3	ZrO ₂ NPs	H ₂ O	40	58
4	ZrO ₂ NPs	CH ₃ CN	30	50
5	ZrO ₂ NPs	DCM	30	40
6	ZrO ₂ NPs	DMF	30	48
7	ZrO ₂ NPs	THF	30	40
8	ZrO ₂ NPs	MeOH	12	60
9	ZrO ₂ NPs	EtOH	7	73
10	ZrO ₂ NPs	EtOH:H ₂ O (6:1)	7	78
11	ZrO ₂ NPs (5 mol %)	EtOH:H ₂ O (4:1)	10	76
12	ZrO ₂ NPs	EtOH:H ₂ O (4:1)	3, 5, 7	60, 97, 97
13	ZrO ₂ NPs (15 mol %)	EtOH:H ₂ O (4:1)	7	96
14	ZrO ₂ NPs	EtOH:H ₂ O (2:1)	10	68
15	ZrO ₂ NPs	EtOH:H ₂ O (1:1)	10	56


^aIsolated yield; Reaction conditions: Substituted 4-oxo-4H-benzopyran-3-carbaldehydes (4-oxo-4H-chromene-3-carbaldehyde) 1 (1 mmol), phenyl hydrazine 2 (1 mmol), ethyl acetoacetate 3 (1 mmol) and ZrO₂ NPs (10 mol %) in ethanol-water (4-1) was stirred at room temperature and reflux.

TABLE-2
ZrO₂ NPs CATALYZED SYNTHESIS OF CHROMENE-PYRAZOLONE DERIVATIVES

Product	R ₁	R ₂	R ₃	R ₄	Time (min)	Yield (%) ^a	m.p. (°C)
4a	Cl	H	H	Cl	5	97	291-293
4b	H	H	CH ₃	H	7	84	239-241
4c	H	H	Br	H	7	90	234-235
4d	H	CH ₃	Cl	H	7	95	252-254
4e	H	Cl	Cl	H	5	94	267-269
4f	H	CH ₃	CH ₃	H	7	81	249-251
4g	Cl	H	H	H	7	89	219-221
4h	H	H	Cl	H	7	89	235-237
4i	Cl	H	Cl	H	5	92	292-293
4j	H	CH ₃	H	H	7	84	198-201
4k	H	CH ₃	H	CH ₃	7	80	214-215
4l	CH ₃	H	CH ₃	H	7	82	280-283
4m	H	H	H	H	7	88	229-231

^aIsolated yield; Reaction conditions: All the reaction was carried out in equimolar amounts of each compound in 4 mL of water-ethanol, stirred at 60-70 °C.


was investigated by checking its reusability, after each cycle, the ZrO₂ NPs were recovered by centrifugation, washed with hot methanol, dried and reused for successive reactions. First four cycles gave better yield and then gradually decreases (Fig. 4) and which is characterized before used in the reaction by X-ray diffraction, UV-Visible and FT-IR spectroscopy. The important feature for these catalysts is; surface of catalyst

Fig. 4. Reusability of ZrO₂ NPs for the synthesis of chromene-pyrazolones as a model reaction

contains active hydroxyl, oxide groups and Zr⁴⁺ act as Lewis acids which are well reported [24]. The active hydroxide and oxide of nanoparticles plays an important role for cyclization and condensation reaction because of act as both function acid as well as base [25] showing with possible mechanism for the synthesis of chromene-pyrazolones has been described *via* Knoevenagel addition reaction using ZrO₂ NPs as catalyst (Scheme-III). Finally the structures of the compounds 4 were confirmed by spectral data. For example, in the IR spectrum, it gave a peak at 1795 cm⁻¹ due to (C=O) and 1689 cm⁻¹ due to (C=N) of pyrazolinyl moiety. The ¹H NMR spectrum of compound gave two singlet at 7.4 δ (s, 1H, -CH=C-) and 6.7 δ (s, 1H, -HC-O-) due to chromone moiety and one singlet at 2.3δ (s, 3H, -CH₃). The mechanistic path: cyclization and condensation between chromene carbaldehyde, hydrazine and ethyl acetoacetate were shown in Scheme-III.

Conclusion

In the present investigation, chromene-pyrazolone derivatives were successfully synthesized by simple stirring condition using ZrO₂ NPs catalyst *via* multi-component reaction in water ethanol. With the (103), (112) and (101) reflections, XRD pattern confirmed the formation of nano-sized tetragonal ZrO₂ NPs with no extra peak corresponding to monoclinic plane. FT-IR spectra was analyzed for the O-H modes and Zr-O stretching vibrations in pure ZrO₂ NPs. UV-visible spectra of ZrO₂ NPs reveal a band gap value of 4.76 eV. Results revealed that the catalytic activity of ZrO₂ NPs first 4th cycles was considered to be very good. In summary, it can be concluded that the ZrO₂ NPs and water-ethanol used to the preparation of chromene-phenyl pyrazolones is an eco-



Scheme-III: Possible mechanism of chromene-pyrazolone derivatives using of ZrO₂ NPs

friendly, readily available solvent and inexpensive. It was found that the reactions afforded very good yields under simple stirred conditions.

REFERENCES

- M.M. Kandeel, A.M. Kamal, E.K.A. Abdelal and H.A.H. Elshemy, *Eur. J. Med. Chem.*, **59**, 183 (2013); <http://dx.doi.org/10.1016/j.ejmech.2012.11.011>.
- N.K. Shah, N.M. Shah, M.P. Patel and R.G. Patel, *J. Chem. Sci.*, **125**, 525 (2013); <http://dx.doi.org/10.1007/s12039-013-0421-y>.
- J.M. Batista Jr., A.A. Lopes, D.L. Ambrósio, L.O. Regasini, M.J. Kato, V.S. Bolzani, R.M.B. Cicarelli and M. Furlan, *Biol. Pharm. Bull.*, **31**, 538 (2008); <http://dx.doi.org/10.1248/bpb.31.538>.
- R.K. Reddy, Y. Poornachandra, G. Jitender, G. Mallareddy, J.B. Nanubolu, C.G. Kumar and B. Narsaiah *Bioorg. Med. Chem. Lett.*, **25**, 2943 (2015); <http://dx.doi.org/10.1016/j.bmcl.2015.05.041>.
- M. Choi, Y.-S. Hwang, A.S. Kumar, H. Jo, Y. Jeong, Y. Oh, J. Lee, J. Yun, Y. Kim, S. Han, J.-K. Jung, J. Cho and H. Lee, *Bioorg. Med. Chem. Lett.*, **24**, 2404 (2014); <http://dx.doi.org/10.1016/j.bmcl.2014.04.053>.
- F.M. Abdelrazek, P. Metz, O. Kataeva, A. Jäger and S.F. El-Mahrouky, *Arch. Pharm.*, **340**, 543 (2007); <http://dx.doi.org/10.1002/ardp.200700157>.
- S.H. Cho, J.Y. Cho, S.E. Kang, Y.K. Hong and D.H. Ahn, *J. Environ. Biol.*, **29**, 479 (2008).
- L. Abrunhosa, M. Costa, F. Areias, A. Venâncio and F. Proença, *J. Ind. Microbiol. Biotechnol.*, **34**, 787 (2007); <http://dx.doi.org/10.1007/s10295-007-0255-z>.
- A.M.M. Nour, S.A. Khalid, M. Kaiser, R. Brun, W.E. Abdalla and T.J. Schmidt, *J. Ethnopharmacol.*, **129**, 127 (2010); <http://dx.doi.org/10.1016/j.jep.2010.02.015>.
- D.J. Ramón and M. Yus, *Angew. Chem. Int. Ed.*, **44**, 1602 (2005); <http://dx.doi.org/10.1002/anie.200460548>.
- A. Dömling, *Chem. Rev.*, **106**, 17 (2006); <http://dx.doi.org/10.1021/cr0505728>.
- D. Rocchi, J.F. González and J.C. Menéndez, *Green Chem.*, **15**, 511 (2013); <http://dx.doi.org/10.1039/C2GC36221J>.
- L.F. Tietze, *Chem. Rev.*, **96**, 115 (1996); <http://dx.doi.org/10.1021/cr950027e>.
- C.C.A. Cariou, G.J. Clarkson and M. Shipman, *J. Org. Chem.*, **73**, 9762 (2008); <http://dx.doi.org/10.1021/jo801664g>.
- R. Gasparova and M. Lacova, *Molecules*, **10**, 937 (2005); <http://dx.doi.org/10.3390/10080937>.
- B.R. Madje, S.S. Shindalkar, M.N. Ware and M.S. Shingare, *ARKIVOC*, **14**, 82 (2005); <http://dx.doi.org/10.3998/ark.5550190.0006.e10>.
- R.V. Hangarge, D.V. Jarikote and M.S. Shingare, *Green Chem.*, **4**, 266 (2002); <http://dx.doi.org/10.1039/b111634g>.
- B.K. Karale, V.P. Chavan, A.S. Mane, R.V. Hangarge, C.H. Gill and M.S. Shingare, *Synth. Commun.*, **32**, 497 (2002); <http://dx.doi.org/10.1081/SCC-120002395>.
- J. Ding, X. Li, J. Cao, L. Sheng, L. Yin and X. Xu, *Sens. Actuators B*, **202**, 232 (2014); <http://dx.doi.org/10.1016/j.snb.2014.05.061>.
- L. Nakka, J.E. Molinari and I.E. Wachs, *J. Am. Chem. Soc.*, **131**, 15544 (2009); <http://dx.doi.org/10.1021/ja904957d>.
- K. Tomishige, Y. Ikeda, T. Sakaijori and K. Fujimoto, *J. Catal.*, **192**, 355 (2000); <http://dx.doi.org/10.1006/jcat.2000.2854>.
- Q.A. Islam, M.W. Raja, C. Satra and R.N. Basu, *Bull. Mater. Sci.*, **38**, 1473 (2015); <http://dx.doi.org/10.1007/s12034-015-0977-x>.
- E. Karapetrova, R. Platzer, J.A. Gardner, E. Torne, J.A. Sommers and W.E. Evenson, *J. Am. Ceram. Soc.*, **84**, 65 (2001); <http://dx.doi.org/10.1111/j.1151-2916.2001.tb00609.x>.
- Y. Zhao, W. Li, M. Zhang and K. Tao, *Catal. Commun.*, **3**, 239 (2002); [http://dx.doi.org/10.1016/S1566-7367\(02\)00089-4](http://dx.doi.org/10.1016/S1566-7367(02)00089-4).
- A. Saha, S. Payra and S. Banerjee, *Green Chem.*, **17**, 2859 (2015); <http://dx.doi.org/10.1039/C4GC02420F>.